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Abstract
Background: Successful left lateral segment (sectionectomy) and right trisegmentectomy (trisectionec-
tomy) split-liver transplantation (SLT) have been achieved. However, there are few reports of the use of
true right/left splitting in SLT.
Methods: A single-centre retrospective review of true right/left ex vivo split-liver transplants performed
during the period 1993–2010 was conducted. Nine cadaveric liver grafts underwent splitting and the
resultant 18 allografts were used in transplants performed at the study centre.
Results: In the nine right lobe recipients, 10-year patient and graft survival rates were both 74%. There
were no vascular complications, one biliary complication and one re-exploration. In the nine left lobe
recipients, 10-year patient and graft survival rates were 78% and 66%, respectively. Postoperative
complications included six biliary complications, four of which required surgical revision and all of which
occurred within 5 months of transplantation, and two vascular complications, including one early hepatic
artery thrombosis (HAT) and one late HAT, one of which required retransplantation. Five left lobe recipients
required re-exploration, and one patient developed small-for-size syndrome following SLT, which resolved
with conservative measures.
Conclusions: True right/left ex vivo SLT remains a viable option for facilitating the expansion of the adult
cadaver donor pool and allows for excellent patient and graft survival. Postoperative morbidity remains
high, especially in recipients of the left lobe graft, and must be balanced with the benefits to be derived
from transplant.
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Introduction
The deficiency in donor organ availability is the most significant
factor inhibiting the further application of liver transplantation in
patients with end-stage liver disease.1 Split-liver transplantation
(SLT), whereby a deceased donor liver allograft is divided to gen-
erate two allografts suitable for transplantation, was first reported
by Pichlmayr et al. in 1988 as a potential method of expanding the
adult donor organ pool to the paediatric population.2
Initially, SLT entailed splitting off the left lateral segment graft
for the paediatric recipient and allocating the right trisegment
(trisection) graft to a waitlisted adult patient. However, it is the
true right lobe/left lobe SLT procedure that holds the greatest
potential for addressing the severe organ shortage in the adult
population because it allows for the allocation of both partial
grafts to recipients on the adult waitlist. This procedure is techni-
cally more challenging and incurs a potential increase in postop-
erative recipient morbidity as a result of the splitting procedure in
comparison with whole-organ transplantation, and there are few
reports of true right/left allograft splitting.3–7
Previous reports have described the results obtained at this
study centre with SLT in both adult and paediatric patient popu-
lations from 1993 to 2010.8 The current study was performed to
further analyse outcomes in 18 recipients who underwent right
lobe (RL) or left lobe (LL) transplantation following nine ex vivo
liver splitting procedures, with specific attention to donor charac-
teristics, as well as the recipients’ operative course and surgical
morbidity, and longterm survival of these partial liver allografts.
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Materials and methods
The medical records of patients who underwent SLT from 18
September 1993 to 1 July 2010 at the University of California, San
Francisco (UCSF) were retrospectively reviewed. This work was
approved by the Committee for Human Research at UCSF. Long-
term outcomes were assessed through office medical records; for
cases in which this was not possible, survival was assessed via the
Social Security DeathMaster File. Clinical medical records, opera-
tive notes and pathology reports were used to gather data. Addi-
tional recipient data, as well as donor data, were supplied by the
United Network for Organ Sharing (UNOS) as the contractor for
the Organ Procurement and Transplantation Network (OPTN), as
of 30 July 2010.
Graft loss was defined as death or need for retransplantation.
Complications were initially categorized as biliary, vascular,
primary non-function, small-for-size syndrome (SFSS), incisional
hernia or need for re-exploration. Biliary complications were
characterized as leak, stricture or the combination of leak and
stricture. The course of recipients with a biliary complication,
including those with concomitant hepatic artery thrombosis, was
further reviewed to determine the number of non-surgical and/or
surgical interventions. Non-surgical interventions included the
maintenance of a postoperative drain for continued bilious
output, drainage of perihepatic bilious abscesses, endoscopic ret-
rograde cholangiography (ERC) with or without stent placement,
percutaneous transhepatic cholangiography with or without stent
placement, dilation of biliary strictures, simple fistulograms, tube
checks and tube removals.Vascular complications included steno-
sis or thrombosis, and were further characterized as early (within
1 month post-transplant) or late (>1 month post-transplant). The
number and type of all surgical and/or non-surgical interventions
necessary to treat a vascular complication (including retransplan-
tation) were recorded. Kaplan–Meier curves were used to analyse
patient and graft survival. Unless indicated, all means are
expressed as the mean  standard deviation.
True right/left ex vivo SLT procedure
All grafts were split utilizing the ex vivo technique previously
described.8 In brief, the ex vivo split-liver procedure at UCSF was
performed in the following fashion. Care was taken to maintain
the liver allograft submerged in an ice bath at all times. The biliary
anatomy and arterial anatomy were initially delineated with con-
trast radiography (Fig. 1) prior to proceeding with liver splitting.
These images, combined with careful anatomic inspection, not
only allowed an assessment of the liver’s suitability for splitting,
but also provided a blueprint for the splitting procedure. Once the
allograft had been deemed suitable for splitting, the hilar struc-
tures were approached in a posterior fashion, in which the left
portal vein was divided from the main portal trunk, leaving the
main portal vein in continuity with the right portal vein branch in
all but two cases. The left portal vein was left in continuity with the
main portal vein as a result of anatomic concerns in these two
recipients (patient 5-LL was undergoing a third liver transplant;
patient 9-LL had maple syrup urine disease and was donating a
domino graft). If necessary, biliary and arterial anatomy were
further defined during liver splitting with the use of dilute meth-
ylene blue injected through the open end of the common bile duct
(CBD) or hepatic artery. The right hepatic artery was divided
from the proper hepatic artery, leaving the left graft with the
coeliac trunk in all patients but one (patient 8-LL: this donor
allograft had an early bifurcation of the right and left hepatic
arteries at the level of the coeliac axis). The left bile duct was taken
off the main duct, leaving the right hepatic duct in continuity with
the CBD in all cases. The left and middle hepatic veins were
dissected from the vena cava in four patients (patients 1-LL, 6-LL,
7-LL and 8-LL), leaving the vena cava with the right-sided graft. In
the remaining LL recipients, the vena cava was preserved with the
left-sided graft. The decision on which lobe should retain the vena
cava was based upon surgical and anatomic considerations in both
RL and LL recipients. The parenchymal division was accom-
plished using the fracture technique and a combination of ties,
Figure 1 Prior to ex vivo splitting, backtable (a) arteriography and (b) cholangiography are performed to assist in delineation of the relevant
anatomy
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clips and vascular staplers. The cut surface was inspected for leaks
by flushing the hilar structures, and stasis was achieved using silk
ties or sutures. The cut surface was treated with argon beam
coagulation and covered with topical sealant prior to reperfusion.
Transplants were performed in the usual fashion without veno–
venous bypass or T-tubes.
Results
From 1993 to 2010, a total of 107 SLTs in 107 patients were carried
out at UCSF. This cohort included 10 true RL (liver segments
V–VIII) transplants and nine true LL transplants (liver segments
I–IV). Data for one RL recipient were excluded from the final
analysis because the graft was imported. The remaining 18
patients were recipients of nine RL and nine LL grafts generated
after nine donor livers had been split ex vivo at UCSF (Table 1).
Donors
The criteria used at UCSF for optimal donor selection include
the following: brain death of the donor; donor age of <40 years;
donor body mass index (BMI) of <30 kg/m2; a sodium level of
<155 mEq/l (to convert to millimoles per litre, multiply by 1.0);
no more than single-agent vasopressor requirements; minimal
elevations in transaminases; donor hospitalization of <7 days,
and organ downtime of <30 min. The demographics of the true
right/left split-liver donors and causes of death are given in
Table 2. The median age of donors was 19 years (range: 16–40
years). In donors, median height was 183 cm (range: 175–
191 cm), median weight was 83 kg (range: 53–120 kg) and mean
BMI was 26.6 kg/m2.
Right lobe recipients
General demographics, causes of end-stage liver disease and year
of transplant in RL recipients are listed in Table 1. In these recipi-
ents, median age at transplant was 55 years (range: 40–66 years),
median wait time was 128 days (range: 16–2550 days), median
height was 168 cm (range: 142–183 cm), median weight was
68 kg (range: 52–119 kg) and mean BMI was 25.2 kg/m2. Right
lobe recipients had a median match Model for End-stage Liver
Disease (MELD) or Paediatric End-stage Liver Disease (PELD)
score of 29 (range: 15–33), and a median laboratory MELD/PELD
score of 20 (range: 8–33). Four RL recipients had MELD excep-
tion points: these referred to hepatocellular carcinoma in three
patients (patients 5-RL, 6-RL, 9-RL), and to hepatopulmonary
syndrome in one (patient 8-RL). The relevant liver-splitting
anatomy is detailed in Table 3. The median warm ischaemic time
was 40 min (range: 32–61 min), median cold ischaemic time was
9.8 h (range: 6.1–13.4 h), and median estimated blood loss (EBL)
Table 1 Demographic data for recipients of left and right lobe split-liver transplants (n = 18)
Year of transplant Gender Age, years Height, cm Weight, kg Cause of disease
Right lobe (RL) recipients
1-RL 1998 Male 49 167 62 HBV
2-RL 2006 Male 55 142 36 HCV
3-RL 2008 Male 60 160 53 HCV
4-RL 2009 Male 46 178 119 NASH
5-RL 2009 Male 54 170 75 HCV/HCC
6-RL 2009 Female 55 168 91 HCV/HCC
7-RL 2009 Male 66 168 52 HBV
8-RL 2009 Male 57 183 68 HCV/HPS
9-RL 2010 Male 40 163 73 HBV/HCC
Left lobe (LL) recipients
1-LL 1998 Female 62 155 55 HCV
2-LL 2006 Male 18 175 36 PSC
3-LL 2008 Female 48 173 81 PBC
4-LL 2009 Female 65 157 53 PBC
5-LL 2009 Female 16 119 25 Autoimmune
6-LL 2009 Male 14 130 26 MMA
7-LL 2009 Female 2 88 14 PFIC
8-LL 2009 Female 13 127 28 CHF
9-LL 2010 Female 10 137 29 MSUD
CHF, congenital hepatic fibrosis; HBV, hepatitis B virus; HCV, hepatitis C virus; HCC, hepatocellular carcinoma; HPS, hepatopulmonary syndrome;
MMA, methylmalonate aciduria; MSUD, maple syrup urine disease; NASH, non-alcoholic steatohepatitis; PBC, primary biliary cirrhosis; PFIC,
progressive familial intrahepatic cholestasis; PSC, primary sclerosing cholangitis.
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was 1750 ml (range: 700–6000 ml). Ten-year patient survival and
10-year graft survival were both 74%. There were no vascular
complications in RL transplants, and there was one biliary com-
plication, which consisted of concomitant anastomotic stricture
and cut edge leak and was managed by endoscopic retrograde
cholangiopancreatography (Table 4). Additional complications
in the RL recipient group included one requirement for re-
exploration (patient 1-RL). One subject (patient 4-RL, at 119 kg
the largest recipient transplanted) required splenic artery ligation
followed by portocaval shunt creation at the time of SLT as a
result of a high portal systemic pressure gradient after implanta-
tion and thus potential concern for the development of SFSS.
Splenic artery ligation alone was insufficient to reduce the portal
pressure gradient and thus portocaval shunt creation was per-
formed, and the patient recovered without evidence of SFSS in
the postoperative period. Recipient 7-RL received a combined
liver and kidney transplant (CLKT). There were no cases of
primary non-function. Median hospital length of stay (LoS) was
8 days (range: 6–44 days).
Left lobe recipients
General demographics, causes of end-stage liver disease and
year of transplant in LL recipients are listed in Table 1. Left lobe
recipients had a median age at transplant of 16 years (range: 2–65
Table 2 Demographics and cause of death in liver donors
Donor Gender Age, years Height, cm Weight, kg Cause of death
1 Male 16 183 105 CVA/stroke
2 Male 40 188 99 CVA/stroke
3 Male 19 183 87 Head trauma
4 Male 20 191 120 Head trauma
5 Male 17 181 83 Head trauma
6 Male 22 183 83 Head trauma
7 Male 17 175 53 Head trauma
8 Female 20 180 76 Anoxia
9 Male 17 169 82 Head trauma
CVA, cerebrovascular accident.
Table 3 Operative course and relevant anatomy in recipients of right and left lobe split-liver transplants (n = 18)
Caval drainage Biliary drainage Portal anatomy Arterial anatomy
Right lobe (RL) recipients
1-RL Bicaval Duct-to-duct Main portal Right hepatic artery
2-RL Piggyback Duct-to-duct Main portal Right hepatic artery
3-RL Piggyback Duct-to-duct Main portal Right hepatic artery
4-RL Piggyback Duct-to-duct Main portal Right hepatic artery
5-RL Piggyback Duct-to-duct Right portal Right hepatic artery
6-RL Bicaval Duct-to-duct Main portal Right hepatic artery
7-RL Bicaval Duct-to-duct Main portal Right hepatic artery
8-RL Bicaval Duct-to-duct Main portal Right hepatic artery
9-RL Piggyback Duct-to-duct Right portal Right hepatic artery
Left lobe (LL) recipients
1-LL Piggyback Roux-en-Y Left portal Coeliac axis
2-LL Bicaval Roux-en-Y Left portal Coeliac axis
3-LL Bicaval Roux-en-Y Left portal Coeliac axis
4-LL Bicaval Roux-en-Y Left portal Coeliac axis
5-LL Bicaval Roux-en-Y Main portal Coeliac axis
6-LL Piggyback Roux-en-Y Left portal Coeliac axis
7-LL Piggyback Roux-en-Y Left portal Coeliac axis
8-LL Piggyback Roux-en-Y Left portal Left hepatic artery
9-LL Bicaval Roux-en-Y Main portal Coeliac axis
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years),median wait time of 74 days (range: 18–1057 days),median
height of 137 cm (range: 88–175 cm), median weight of 29 kg
(range: 14–81 kg) and a mean BMI of 19.7 kg/m2. Their median
match MELD/PELD score was 28 (range: 10–40) and median
laboratory MELD/PELD score was 21 (range: 0–40). No LL recipi-
ents had MELD exception points. The relevant liver-splitting
anatomy is detailed in Table 3. In LL recipients, median warm
ischaemic time was 36 min (range: 27–65 min), median cold
ischaemic time was 9.7 h (range: 3.6–15.2 h) and median EBL was
1450 ml (range: 500–10000 ml). Ten-year patient survival was
78% and 10-year graft survival was 66%. Vascular and biliary
complications in LL recipients are depicted in Table 4. Five of the
nine patients required re-exploration (patients 1-LL, 2-LL, 3-LL,
5-LL, 6-LL). The largest LL recipient (patient 3-LL, 81 kg) devel-
oped postoperative SFSS, which resolved with conservative man-
agement. Recipients 5-LL and 8-LL underwent CLKT. The LL
graft represented the second liver transplant in recipient 6-LL and
the third in recipient 7-LL. There were no cases of primary non-
function. The median hospital LoS was 40 days (range: 8–148
days).
Discussion
The technical evolution of SLT has largely addressed the needs of
the paediatric population awaiting liver transplantation. The ben-
efits of SLT to the paediatric population are evident, as demon-
strated by decreases in wait time to transplant and in subsequent
waitlist mortality.1 In addition, SLT, unlike reduced-size liver
transplantation, does not deprive an adult patient awaiting trans-
plantation of the opportunity for transplantation. Despite the
higher risk for morbidity to the adult recipient associated with
SLT in comparison with whole-organ transplantation, the appli-
cation of SLT results in a net gain in life-years and successful
transplantation in a greater number of recipients.9 Data suggest
Table 4 Postoperative complications in recipients of right and left lobe split-liver transplants (n = 18)
Vascular Cx Vascular intervention Biliary Cx Biliary intervention Day and cause of
graft failure
Right lobe recipients
1-RL No None No None N/A
2-RL No None No None N/A
3-RL No None No None N/A
4-RL No None No None N/A
5-RL No None No None N/A
6-RL No None No None 346 days; cause of
death unknown
7-RL No None Leak and
stricture
GI-ERCP stent and angioplasty N/A
8-RL No None No None 44 days; death of
cardiopulmonary cause
9-RL No None No None N/A
Left lobe recipients
1-LL No None No None 4255 days; cause of
death unknown
2-LL No None No None N/A
3-LL No None Leak IR: stent; surgical revision (1 month)b N/A
4-LL No None Leak IR: drain; surgical revision (0 months)b 93 days; death of sepsis
5-LL Early HAT
(0 months)a
IR: thrombectomy,
angioplasty, tPA
Stricture IR: stent and drain N/A
6-LL No None No None N/A
7-LL No None Stricture IR: stent; surgical revision (5 months)b N/A
8-LL No None Leak IR: drain 20 days; death of sepsis
9-LL Late HAT
(2 months)a
Retransplantation Leak IR: drain; surgical revision (2 months)b 80 days; late HAT
aTiming of vascular complication.
bTiming of biliary surgical revision.
Cx, complication; ERCP, endoscopic retrograde cholangiopancreatography; GI, gastrointestinal; HAT, hepatic artery thrombosis; IR, interventional
radiology; N/A, not applicable; tPA, tissue plasminogen activator.
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that, with proper donor and recipient selection, results similar to
those of whole-organ liver allografts can be obtained in recipients
of split-liver transplants.10 However, SLT currently accounts for
approximately 4% of liver transplants performed each year in the
USA,11 although it is estimated that up to 25% of donor allografts
are suitable for splitting.1
Theuse of true right/left SLT for two adult recipients (or an adult
and an adolescent recipient) has yet to gain wider acceptance, and
still holds potential as a method to address the growing waitlisted
adult population.The increased technical demands associatedwith
true right/left SLT, concern for the potential of inadequate func-
tional hepatic mass for the adult recipient post-transplant (SFSS),
as well as the recognition of an increased rate of vascular or biliary
complications, are likely to have contributed to scepticism on the
applicationof true right/left SLT.Considerationof a varianceby the
OPTN which allows the splitting centre to make the decision on
the second recipient of the SLT has the potential to increase the
utilization of this technique and these organs.
The present experience with ex vivo true right/left SLT demon-
strates that excellent longterm patient and graft survival can be
obtained. However, this form of liver transplantation must be
undertaken on the understanding that, in its current state, it is
associated with increased postoperative morbidity, especially in
recipients of the LL graft. Indeed, although only seven of the
present 18 recipients experienced a biliary complication, six of
these were recipients of LL grafts. Two patients receiving LL grafts
also experienced vascular complications. These complications are
not unique to SLT: incidences of biliary strictures are reported to
be 5–15% following deceased donor liver transplantation (DDLT)
and 28–32% following living donor liver transplantation
(LDLT).12 Although the biliary complication rate associated with
LL transplants could potentially be minimized by maintaining the
CBD with the LL graft, this is likely to result in the transplantation
of an RL graft with multiple ducts. Given the likely reduction in
the risk for biliary complications with the graft containing the
CBD, during the splitting procedure consideration should be
given to whether the CBD should be retained with the liver
segment to be transplanted into the recipient who drew the initial
liver allocation. The latter is akin to the maintenance of the coeliac
artery with the left lateral segment in an adult/child SLT.
No recipients in the present series developed primary non-
function, a once feared complication of ex vivo liver splitting.13
Efforts were made to retain a graft weight : recipient weight ratio
of >1.0% for all SLTs by carefully selecting recipients according
to body weight. Indeed, the average weight of an RL recipient in
this series was 70 kg and that of an LL recipient was 39 kg. The
only recipient to develop SFSS was the largest (81 kg) recipient
of an LL graft and this patient was amenable to conservative
management with full symptom resolution. The largest trans-
plant recipient in this series (recipient 4-RL, 119 kg) received an
RL graft and underwent splenic artery ligation followed by por-
tocaval shunt at the time of liver transplant to serve as inflow
modulation for the prevention of SFSS. Indeed, it has been pre-
viously demonstrated that living donor LL grafts with a
graft : recipient weight ratio of <0.8 can be safely used if a hemi-
portocaval shunt is constructed to attenuate the associated portal
hyperperfusion.14 The principle of portal inflow modulation
used in LDLT may need to be applied in recipients of SLT grafts
in order to minimize the risk for SFSS and to facilitate the
expanded use of SLT grafts to larger recipients.
Although significant morbidity is associated with SLT, this
should be considered in the context of the survival benefit to be
derived by transplantation in the setting of an expanding demand
that greatly outweighs current supply. The latter serves to justify
the pursuit of living liver donation, which in the USA is per-
formed at the same rate as SLT, and appears to be focused on the
areas of greatest need.15 Indeed, it should be noted that recipient
morbidity following LDLT is similar to that seen in SLT. Results
from the Adult-to-Adult Living Donor Liver Transplantation
(A2ALL) Cohort Study demonstrated that recipients of LDLT had
a 31.8% incidence of biliary leak, a 26.2% incidence of unplanned
re-exploration, a 6.5% incidence of hepatic artery thrombosis,
and a 2.9% incidence of portal vein thrombosis, all of which were
higher than in recipients of whole-organ deceased donor allo-
grafts.16 Furthermore, SLT, unlike LDLT, carries no risk to a
healthy donor. Indeed, results from the A2ALL cohort have dem-
onstrated that up to 40% of living liver donors experience post-
operative complications.17 If the intended adult or adolescent
recipient requires partial liver transplantation as a result of donor
size considerations, he or shemay assume a higher risk for surgical
morbidity by requesting SLT for the benefit of expediting the
transplant rather than remaining on the waitlist. However, if the
intended recipient is facilitating SLT, in lieu of accepting a whole
organ, this recipient is assuming a higher risk for surgical mor-
bidity for the benefit of allowing an additional patient to undergo
expedited liver transplantation. The latter is akin to the risk a
living liver donor must assume. In this situation, the intended
recipient should be provided with the biliary and vascular
anatomy that minimizes this risk. The recipient of the other
portion of the liver should be told of this decision and must be
willing to accept the potential for a higher surgical risk along with
the benefit of expedited transplantation.
As the present group has previously reported, appropriate
donor and recipient selection are essential to optimize the results
of SLT.8 The laboratory MELD scores of 21 in both LL and RL
recipients represent an institutional preference for the use of SLT
in patients with low true MELD scores (which precludes these
patients from contending for DDLT within this study’s donor
service area) and/or in patients who require expedited transplan-
tation. The selection of a potential SLT recipient is based on the
patient’s size, severity of disease, risk for waitlist death and risk for
waitlist dropout. Suitable adult recipients for SLT are evaluated
and consented by the transplant surgical team in advance of trans-
plant in order to ensure they obtain a full understanding of the
risks and benefits of partial liver transplantation. The grafts trans-
planted into the four RL recipients for whom exception points
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were listed were initially allocated to the LL recipients, but the RL
recipients pursued SLT as a form of expediting transplantation.
It has been demonstrated that adult split-liver recipients
include a higher proportion of women than do adult whole-organ
recipients.9 Furthermore, women have significantly increased
odds of undergoing LDLT in comparison with male transplant
recipients.15 The greater need for partial liver transplantation in
women, whether it be through SLT or LDLT, probably reflects a
combination of: (i) a disparity in MELD score-based liver alloca-
tion caused by an underestimation of the degree of renal dysfunc-
tion in female patients (as a result of the inclusion of the serum
creatinine level rather than the glomerular filtration rate in the
calculation of the MELD score), and (ii) the smaller size of female
recipients, which hampers appropriate donor–recipient organ
matching at the time of initial organ offer. Partial liver transplan-
tation, using SLT or LDLT, not only allows for expedited trans-
plantation to the female recipient, but also allows for an
appropriately sized, smaller graft. Indeed, in the present series
78% of LL grafts were transplanted to female recipients, whereas
89% of RL grafts were transplanted to male recipients.
This study represents an observational, retrospective review of a
single-centre experience with ex vivo true right/left SLT. The
population of interest was represented by a small number of
patients, which represents a limitation of this study. Although this
series includes only 18 patients, it represents one of the larger
series of true right/left SLT, especially with utilization of the ex
vivo technique. Humar et al. reported the first North American
series of six adult/adult SLT procedures, performed in situ, dem-
onstrating patient and graft survival of 83% at a mean follow-up
of 9 months.6 An updated report on the use of in situ splitting in
31 adult patients documented graft and patient survival of 74% at
3 years post-transplant, but without sub-classifying LL and RL
graft and patient survival.10 The Paul Brousse group has extensive
experience with ex vivo SLT and in 2001 reported a series of 34
recipients of SLT with 2-year patient and graft survival of 74% and
74%, respectively, for RL split grafts, and 64% and 43%, respec-
tively, for LL split grafts.7 It should be noted that only eight of the
34 recipients received true right/left ex vivo SLT as the vast major-
ity of LL grafts in this series were transected through segment IV
and contained solely the left hepatic vein.7 Broering et al. reported
their results with a combination of in situ and ex vivo right/left
SLT in 35 patients using a technique of vena caval and middle
hepatic vein splitting.18 They reported an overall biliary compli-
cation rate of 29%, with patient and graft survival at 27 months of
87.5% and 75.0%, respectively, for RL grafts, and 89.5% and
84.0%, respectively, for LL grafts.
In summary, this experience with ex vivo true right/left SLT
demonstrates that excellent longterm patient and graft survival
can be obtained, but that significant morbidity occurs in recipi-
ents of LL split grafts. Optimization of the technical aspects of
liver splitting, with attention to the left-side biliary system, is
warranted to reduce postoperative morbidity. Although a propor-
tion of the LL recipients in the present series were adolescents,
further understanding of various techniques for portal inflow
modulation for the prevention of SFSS, such as the application of
hemi-portocaval shunts and/or splenic artery ligation, will poten-
tially allow for the expansion of both RL and LL SLT to an adult
population that includes larger patients.
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